Pharmacological approaches to inhibit endogenous glucose production as a means of anti-diabetic therapy.
about
The binding of β- and γ-cyclodextrins to glycogen phosphorylase b: Kinetic and crystallographic studiesFR258900, a potential anti-hyperglycemic drug, binds at the allosteric site of glycogen phosphorylaseEffect of medicinal mushrooms on blood cells under conditions of diabetes mellitusMB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes.Current therapies and emerging drugs in the pipeline for type 2 diabetes.Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors.Selective reversible inhibition of liver carnitine palmitoyl-transferase 1 by teglicar reduces gluconeogenesis and improves glucose homeostasis.Gene expression profile analysis of type 2 diabetic mouse liver.Defective glycogenesis contributes toward the inability to suppress hepatic glucose production in response to hyperglycemia and hyperinsulinemia in zucker diabetic fatty ratsDual mode of glucagon receptor internalization: role of PKCα, GRKs and β-arrestins.Mice expressing reduced levels of hepatic glucose-6-phosphatase-α activity do not develop age-related insulin resistance or obesity.Glucagon as a target for the treatment of Type 2 diabetes.(6R,9S)-6"-(4"-hydroxybenzoyl)-roseoside, a new megastigmane derivative from Ouratea polyantha and its effect on hepatic glucose-6-phosphatase.Crystallographic studies on acyl ureas, a new class of glycogen phosphorylase inhibitors, as potential antidiabetic drugs.Association of immunosuppressant-induced protein changes in the rat kidney with changes in urine metabolite patterns: a proteo-metabonomic study.Effect of geniposide, a hypoglycemic glucoside, on hepatic regulating enzymes in diabetic mice induced by a high-fat diet and streptozotocin.Sensitivity of glycogen phosphorylase isoforms to indole site inhibitors is markedly dependent on the activation state of the enzyme.Evidence against glycogen cycling of gluconeogenic substrates in various liver preparations.Application of (13)C-filtered (1)H NMR to evaluate drug action on gluconeogenesis and glycogenolysis simultaneously in isolated rat hepatocytes.Antidiabetic Potential of Monoterpenes: A Case of Small Molecules Punching above Their Weight.Hypoglycemic effects of Ganoderma lucidum polysaccharides in type 2 diabetic mice.First proof of pharmacology in humans of a novel glucagon receptor antisense drug.The potential beneficial effects of phenolic compounds isolated from A. pilosa Ledeb on insulin-resistant hepatic HepG2 cells.Anti-diabetic activity of quercetin extracted from Phyllanthus emblica L. fruit: In silico and in vivo approaches.
P2860
Q27641882-39772B62-8E61-4D11-84E6-121EB217E3DEQ27646498-E61F345F-0E92-4672-9259-164512DACD0EQ33706752-C3D65D9D-667A-4C2E-BF8B-A0727184261AQ33833542-8E2E7800-0208-4567-B06D-A36221A8378EQ33928941-8E8F0B5F-9B27-41F7-BADC-8AB15DD86779Q34328200-D22D4F14-A2CA-4AE0-B5D4-17CC9F0DB775Q34527222-87753065-6C2A-49A2-90CC-BF9727F274B8Q34613248-EB248DDB-F291-4AB3-99DF-7CB715D42340Q35180025-365C46B7-9FFB-4BEB-9E71-BC6DB74AB5F8Q35585071-E0C78C24-BA8E-47B7-BE4C-E0645B461197Q35999250-7162A7A3-E4C2-4011-8287-63F8953DA1AFQ36158732-8AD158BA-73D6-44BB-947E-2E3DCA3C21A2Q36242728-E06C0ECC-5819-49B6-8E20-A7215D18E02FQ36476814-72E75DDB-6EE3-4A65-B21B-9ADDEF8C8F70Q37639949-F35FB79D-B851-4F89-B213-D1BED882D886Q37728252-5854B9A9-2F4C-4043-AB49-BF30FC415705Q41603403-8E618941-6FD1-4E14-9CDC-902708958537Q44013196-77D22EA6-7265-4190-B249-9A97FE01E73FQ44119585-10B4862F-AE5A-4530-A721-56D1186E3A8CQ47173290-0E739F1B-0A90-4DBD-AF2F-4DB1ADFE3457Q47815290-D90B78C1-5425-4481-837A-8258F3B863CBQ51056430-CAE8CC40-E0FD-492D-BD23-5E712A128017Q51430671-E7E6BD45-B64D-4652-850D-279D622D3396Q55006408-BF564F3A-5711-4142-9049-60B2140D6559
P2860
Pharmacological approaches to inhibit endogenous glucose production as a means of anti-diabetic therapy.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Pharmacological approaches to ...... eans of anti-diabetic therapy.
@ast
Pharmacological approaches to ...... eans of anti-diabetic therapy.
@en
Pharmacological approaches to ...... eans of anti-diabetic therapy.
@nl
type
label
Pharmacological approaches to ...... eans of anti-diabetic therapy.
@ast
Pharmacological approaches to ...... eans of anti-diabetic therapy.
@en
Pharmacological approaches to ...... eans of anti-diabetic therapy.
@nl
prefLabel
Pharmacological approaches to ...... eans of anti-diabetic therapy.
@ast
Pharmacological approaches to ...... eans of anti-diabetic therapy.
@en
Pharmacological approaches to ...... eans of anti-diabetic therapy.
@nl
P2093
P356
P1476
Pharmacological approaches to ...... means of anti-diabetic therapy
@en
P2093
J G McCormack
M Kristiansen
P304
P356
10.2174/1381612013397393
P577
2001-09-01T00:00:00Z